Daclatasvir/Asunaprevir/Beclabuvir regulates innate immunity by inhibition of nonstructural 5B and suppresses liver fibrosis development
Phase of Trial: Phase IV
Latest Information Update: 09 Nov 2018
At a glance
- Drugs Asunaprevir/becabluvir/daclatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 30 Oct 2018 Status changed from active, no longer recruiting to discontinued.
- 17 Apr 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 04 May 2017 New trial record